Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Sandberg

Endocrinology, Diabetes & Metabolism Flemington, NJ Medical Doctor

NPI 1770557837 CMS profile 80039

9100 Wescott Dr, Suite 101, Flemington, NJ 08822

Open in the dashboard

General payments

$566,757

1,603 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marc Sandberg of Flemington, NJ is reported in the CMS Open Payments database as having received $566,757 across 1,603 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,524 172
2024 General $84,177 240
2023 General $71,095 216
2022 General $73,774 212
2021 General $84,676 231
2020 General $83,353 238
2019 General $123,159 294

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Sandberg
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Marc Sandberg were reported at $46,524. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Marc Sandberg Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $123,159 $494 $123–$2,253 $163
2020 $83,353 $335 $85–$1,841 $114
2021 $84,676 $398 $88–$1,981 $132
2022 $73,774 $364 $88–$1,568 $149
2023 $71,095 $420 $113–$1,614 $160
2024 $84,177 $440 $121–$1,646 $164
2025 $46,524 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $186,922 377 payments
  2. Sanofi-Aventis U.S. LLC $148,820 172 payments
  3. Novo Nordisk Inc $110,905 235 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $26,995 83 payments
  5. Valeritas, Inc. $24,823 31 payments
  6. Corcept Therapeutics $15,550 91 payments
  7. AstraZeneca Pharmaceuticals LP $10,354 44 payments
  8. Intuity Medical Inc $10,320 23 payments
  9. AbbVie, Inc. $8,079 33 payments
  10. Janssen Pharmaceuticals, Inc $6,297 20 payments
  11. Other $17,693 494 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $504,388 355 payments
  2. Food and Beverage $23,469 1,071 payments
  3. Travel and Lodging $20,675 152 payments
  4. Consulting Fee $13,084 6 payments
  5. Honoraria $4,750 4 payments
  6. Education $391 15 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $83,163 143 payments
  2. Ozempic $58,474 128 payments
  3. HUMULIN $42,941 64 payments
  4. SOLIQUA 100/33 Endocrine & Metabolic Diseases $38,497 36 payments
  5. JARDIANCE $36,374 84 payments
  6. RYBELSUS $36,115 98 payments
  7. TZIELD $27,083 30 payments
  8. V-GO $26,623 35 payments
  9. TOUJEO $22,543 22 payments
  10. SOLIQUA 100/33 Diabetes $21,232 37 payments
  11. Other $157,725 1,142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

5,875

Median for Endocrinology: 1,959

Drug cost

$3,637,120

Median for Endocrinology: $890,201

Branded share of claims

76.1%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 486 $661,407
Trulicity Dulaglutide Brand 321 $455,014
Mounjaro Tirzepatide Brand 318 $403,419
Jardiance Empagliflozin Brand 293 $295,280
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 163 $225,868
Synjardy Xr Empagliflozin/Metformin Hcl Brand 196 $213,359
Tresiba Flextouch U-200 Insulin Degludec Brand 171 $160,134
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 109 $110,050
Farxiga Dapagliflozin Propanediol Brand 55 $83,586
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 55 $74,476

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$106,467

Of which drugs: $1,406

Medicare patients

472

Average age 73

Services billed

2,137

252 women, 220 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Arthritis 40%
Ischemic heart disease 39%
Chronic kidney disease 39%
Depression 22%
Osteoporosis 22%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 19 20 $1,296

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$32,635 318 —
TZIELD
$17,045 — —
JARDIANCE
$8,612 293 —
Ozempic
$6,112 486 —
Korlym
$5,903 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

1,603 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record